Demonstration Programs, 370 L'Enfant Promenade, S.W., Fifth Floor, Washington, D.C. 20447, Attention: Richard Saul—(202) 401–9341; Anna Guidery—(202) 401–5318.

This Notice is accessible on the OCS Electronic Bulletin Board for downloading through your computer modem by calling 1–800–627–8886. For assistance in accessing the Bulletin Board, a Guide to Accessing and Downloading is available from Ms. Minnie Landry at (202) 401–5309.

The Catalog of Federal Domestic Assistance number for this program is 93.568.

I. Clarification of Definition

A. Section 2607B(e)(2)(A) of the Low-Income Home Energy Assistance Act of 1981, as amended, requires that each State REACH Plan include ''an assurance that such State will deliver services through community-based nonprofit entities in such State * * *''

B. Section 2607B(e)(2)(B) requires that ''in awarding grants or entering into contracts to carry out its REACH initiative, the State will give priority to organizations that—

(i) are described in section 673 of the Community Services Block Grant Act (42 U.S.C. 6863 *et seq.*) * * *'' That is, priority is to be given to Community Action Agencies. (This is one of three criteria for priority consideration.)

C. In its Program Announcement of July 5, 1996 (OCS–96–08), 61 FR 35518–35545, OCS included a definition of ''Community-based, nonprofit'' that defined it as ''a corporation or association * * *'' which has caused some confusion among prospective applicants as to whether a public Community Action Agency which is a unit of local government is eligible to be the ''community-based nonprofit entity'' through which REACH services are to be delivered. The answer is yes. ''Community-based nonprofit entities'' includes organizations described in section 673 of the Community Services Block Grant Act that are public agencies or entities such as public Community Action Agencies that are a unit of local government.

Dated: July 19, 1996.

Donald Sykes,

Director, Office of Community Services.

[FR Doc. 96–18830 Filed 7–23–96; 8:45 am]

BILLING CODE 4184–01–P

Food and Drug Administration

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

Advisory Committee for Pharmaceutical Science (formerly Generic Drugs Advisory Committee)

Date, time, and place. August 15, 1996, 8 a.m., and August 16, 1996, 7:30 a.m., Holiday Inn—Gaithersburg, Goshen Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Type of meeting and contact person. Open committee discussion, August 15, 1996, 8 a.m. to 1 p.m.; open public hearing, 1 p.m. to 2 p.m., unless public participation does not last that long; open committee discussion, 2 p.m. to 6:30 p.m.; open committee discussion, August 16, 1996, 7:30 a.m. to 10 a.m.; Kimberly L. Topper, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Advisory Committee for Pharmaceutical Science, code 12539. Please call the hotline for information concerning any possible changes.

General function of the committee. The committee gives advice on scientific and technical issues concerning the safety and effectiveness of human generic drug products for use in the treatment of a broad spectrum of human diseases.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before August 1, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. On August 15, 1996, the committee will discuss the Biopharmaceutics Drug Classification System and Individual Bioequivalence. On August 16, 1996, the committee will discuss Product Quality Research, Laboratory-Based Clinical Pharmacology Research, and Clinic-Based Clinical Pharmacology Research.

Joint Meeting of the Advisory Committee for Pharmaceutical Science and the Pulmonary and Allergy Drugs Advisory Committee

Date, time, and place. August 16, 1996, 10 a.m., Holiday Inn—Gaithersburg, Goshen Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Type of meeting and contact person. Open committee discussion, 10 a.m. to 11:30 a.m.; open public hearing, 11:30 a.m. to 12:30 p.m., unless public participation does not last that long; open committee discussion, 12:30 p.m. to 3:30 p.m.; Kimberly L. Topper, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Advisory Committee for Pharmaceutical Science, code 12539. Please call the hotline for information concerning any possible changes.

General function of the committees. The Advisory Committee for Pharmaceutical Science gives advice on scientific and technical issues concerning the safety and effectiveness of human generic drug products for use in the treatment of a broad spectrum of

human diseases. The Pulmonary-Allergy Drugs Advisory Committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in the treatment of pulmonary disease and diseases with allergic and/or immunologic mechanisms.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before August 1, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committees will discuss Bioequivalence of Albuterol Metered Dose Inhalers (MDI's).

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this Federal Register notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: July 15, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–18614 Filed 7–23–96; 8:45 am]

BILLING CODE 4160–01–F

Health Care Financing Administration

[R–131]

Agency Information Collection Activities: Submission for OMB Review; Comment Request

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, has submitted to the Office of Management and Budget (OMB) the following proposal for the collection of information. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Collection Request: Reinstatement, without change, of a previously approved collection for which approval has expired; *Title of Information Collection:* Information Collection Requirements in BPD–458–F, Section 411.408(d)(2) and (f); *Form No.:* HCFA–R–131; *Use:* Physicians who do not accept assignment may bill a patient for services denied by Medicare as ''not reasonable and necessary,'' if they informed the patient, prior to furnishing the services, that Medicare was likely to deny part B payments for services and the patient, after being so informed, agrees to pay for the services. *Frequency:* On occasion; *Affected Public:* Individuals or Households; *Number of Respondents:* 237,322; *Total Annual Responses:* 925,904; *Total Annual Hours Requested:* 115,738.

To request copies of the proposed paperwork collections referenced above, E-mail your request, including your address, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections should be sent within 30 days of this notice directly to the OMB Desk Officer designated at the following address: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: July 16, 1996.

Edwin J. Glatzel,

Director, Management Planning and Analysis Staff, Office of Financial and Human Resources, Health Care Financing Administration.

[FR Doc. 96–18763 Filed 7–23–96; 8:45 am]

BILLING CODE 4120–03–U